Clinical Library

The article is intended to assess the injection techniques in contrast imaging. Please visit PubMed for the full text article.

Authored by Brad Keller, Ph.D, Director, Clinical Research Breast Health, Hologic, Inc., Ashwini Kshirsagar, Ph.D, Chief Scientist, Clinical Solutions, Research and Development, Hologic, Inc. and Andrew Smith, Ph.D., Vice President, Image Research Breast Health, Hologic. Inc.  This whitepaper documents how radiologists demonstrated clinical superiority,measured by significantly increased area under the ROC curve, when reviewing tomosynthesis cases with the Genius AI Detection information compared to reviewing the cases without the information.

Brad Keller, Ph.D, Director, Clinical Research Breast Health, Hologic, Inc., Ashwini Kshirsagar, Ph.D, Chief Scientist, Clinical Solutions, Research and Development, Hologic, Inc. and Andrew Smith, Ph.D., Vice President, Image Research Breast Health, Hologic. Inc.  This whitepaper documents how Hologic's product, 3DQuorum 6-mm slices known as SmartSlices can significantly reduce the number of slices and file sizes in a tomosynthesis dataset, while maintaining clinical performance compared to 1-mm datasets. The fewer number of total slices in the study allows a decrease in radiologist interpretation time, saving on average 1 hour per reader in an 8-hour day.

  Authored by Georgia Giakoumis Spear, M.D., this white paper will discuss her experience at NorthShore University Health System as they adopted proven technological advances to increase their ability to detect breast cancers at the earliest stage.  

Study Goal: Quality assurance initiative to determine the minimum number of calcification-containing stereotactic biopsy specimens sufficient for pathologic diagnosis and immunohistochemistry (IHC) in cases of malignancy.   Please visit PubMed for the full text article.  

This article is intended to compare case delays in all patients undergoing breast conserving surgery (BCS) with wire localization in 2017 with all patients undergoing BCS with a radiofrequency identification tag system.   Please visit PubMed for the full text article.  

  A prospective, single-center pilot study evaluated the effectiveness of the FDA-cleared Radiofrequency Identification Localization System (RFLS).   Please visit PubMed for the full text article.  

The article is intended to assess the feasibility of using RFID technology to localize nonpalpable breast lesions.   Please visit PubMed for the full text article.  

The article is intended to assess the safety and performance of a radiofrequency identification tag to localize nonpalpable breast lesions for surgical excision. Please visit PubMed for the full text article.

Authored by Alejandro Tejerina, MD, this white paper will cover the advances in breast screening technology, most notably tomosynthesis, are enabling us to visualize subtle lesions, not previously seen on 2D images. However, the improvements in imaging quality and specificity provided by tomosynthesis pose challenges to our protocols for the management of lesions identified with the technology.    

Authored by Lars Grimm, MD, MHS, this white paper will cover the benefits of tomosynthesis guided biopsy in comparison to traditional two-dimensional mammographic guided biopsies. Specifically, this paper will apply to the Hologic Affirm® Prone Biopsy System and the Affirm® Breast Biopsy Guidance System for the Selenia® Dimensions® and 3Dimensions™ mammography Systems.  

This prospective study has two objectives. The first objective is compare single reading of tomosynthesis examinations to double reading of 2D examinations. The second objective is to assess whether 2D FFDM have any added value when using synthesized 2D mammography (s2D) together with digital breast Tomosynthesis. Please visit PubMed for the full text article.